Philip Livingston and Friedhelm Helling

U.S. Serial No.: Filed :

08/477,147 June 7, 1995

Page 2

Fant

being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the Keyhole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant.--

--62.

(Amended) The composition of claim 57, wherein the immunological adjuvant is a monophospholipid, a non-ionic block copolymer or a cytokine [ganglioside is conjugated to Keyhole Limpet Hemocyanin].--

--63.

(Amended) The composition of claim 57, wherein the adjuvant is a [carbohydrate] <u>saponin</u> derivable from the bark of a <u>Ouillaja saponaria Molina</u> tree.--

--64.

(Amended) The composition of claim 63, wherein the [carbohydrate] saponin is QS-21.--

--71.

(Amended) A method of stimulating or enhancing antibody production in a subject which comprises administering to the subject an effective amount of a composition comprising a ganglioside conjugated through [the] a ceramide-derived carbon [portion] of the ganglioside to a Keyhole Limpet Hemocyanin or a derivative thereof and an adjuvant, the amounts of such conjugated ganglioside and such adjuvant being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the Keyhole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant, so as to thereby stimulate or enhance antibody production in the subject. --

--72.

(Amended) A method of preventing or treating a cancer in

Philip Livingston and Friedhelm Helling

U.S. Serial No.:

08/477,147 June 7, 1995

Filed Page 3

> a subject which comprises administering to/the subject an effective cancer preventing or treating /amount of [the] a composition a ganglioside conjugated through a ceramide-derived carbon of the ganglioside to Keyhole Limpet Hemocyanin or a derivative thereof and an adjuvant, the amounts of such conjugated ganglioside and such adjuvant being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the Kethole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant, so as to thereby prevent or treat a cancer in a subject $[\phi f]$ claim 57].--

- --78. (New) The method of claim 7/1, wherein the cancer is of epithelial origin. --
- (New) The method of claif 71, wherein the cancer is of --79. neuroectodermal origin.;
- The method of claim 79, wherein the cancer of --80. neuroectodermal origi/n is a melanoma.--
- (New) The method of claim 71, wherein the administering --81. is effected at two or more sites.--
- --82. (New) The method of claim 81, wherein the administering is effected at/three sites.--
- (New) The method of claim 71, wherein the immunological --83. adjuvant is a monophospholipid A, a non-ionic block copolymer/or a cytokine. --
- (New) The method of claim 71, wherein the wherein the --84.

Philip Livingston and Friedhelm Helling

U.S. Serial No.:

08/477,147 June 7, 1995

Filed Page 4

adjuvant is a saponin derivable from the bark of a Quillaja saponaria Molina tree.--

- --85. (New) The method of claim 84, wherein the saponin is QS-
- --86. (New) The method of claim 72, wherein the immunological adjuvant is a monophospholipid A, a non-ionic block copolymer or a cytokine.
- --87. (New) The method of claim 72, wherein the adjuvant is a saponin derivable from the bark of a <u>Quillaja saponaria</u>

 <u>Molina</u> tree.--

--88. (New) The method of claim 87, wherein the saponin is QS-

(New) A method/of preventing relapse of a cancer in a --89. subject which comprises administering to the subject an cancer relapse preventing effective amount composition \not comprising a ganglioside conjugated through a ceramide-derived carbon of the ganglioside to a Keyhole Limpet Hemocyanin or a derivative thereof and an adjuvant, khe amounts of such conjugated ganglioside and such adjuvant being effective to stimulate or enhance antibody/production in a subject, and a pharmaceutically acceptable carrier, wherein the Keyhole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant so as to thereby prevent relapse of a cancer in the subject. --

--90. (New) The method of claim 89, wherein the cancer is of epithelial origin.--

Fyt

Philip Livingston and Friedhe/1m Helling

U.S. Serial No.: Filed

08/477,147 June 7, 1995

Page 5

- --91. (New) The method of claim 89, wher in the cancer is of neuroectodermal origin. --
- (New) The method of claim 91, wherein the cancer of --92. neuroectodermal origin is a melanoma. --
- (New) The method of claim 89, wherein the administering --93. is effected at two or more /sites.--
- --94. (New) The method of clain 93, wherein the administering is effected as three sites.-
- (New) The method of claim 89, wherein the immunological --95. adjuvant is a monophospholipid A, a non-ionic block copolymer or a cytokine.--
- (New) The method ϕ f claim 89, wherein the adjuvant is a --96. saponin derivable from the bark of a Quillaja saponaria Molina tree.--
- (New) The method of claim 96, wherein the saponin is QS---97. 21.--
- --98. (New) The / composition of claim 57, wherein the conjugation of the ganglioside is through a carbon derived ffrom a cleavage of a double bond in the ceramide portion bf the ganglioside.--
- claim the --99. (New) The composition of 57, wherein conjugation of the ganglioside is through a carbon derided from a ceramide double bond to the Keyhole Limpet Hemocyanin or a derivative thereof. --